504 related articles for article (PubMed ID: 29525074)
1. Nanoscale artificial antigen presenting cells for cancer immunotherapy.
Rhodes KR; Green JJ
Mol Immunol; 2018 Jun; 98():13-18. PubMed ID: 29525074
[TBL] [Abstract][Full Text] [Related]
2. Biologically Inspired Design of Nanoparticle Artificial Antigen-Presenting Cells for Immunomodulation.
Hickey JW; Vicente FP; Howard GP; Mao HQ; Schneck JP
Nano Lett; 2017 Nov; 17(11):7045-7054. PubMed ID: 28994285
[TBL] [Abstract][Full Text] [Related]
3. Biodegradable Cationic Polymer Blends for Fabrication of Enhanced Artificial Antigen Presenting Cells to Treat Melanoma.
Rhodes KR; Isser A; Hickey JW; Ben-Akiva E; Meyer RA; Kosmides AK; Livingston NK; Tzeng SY; Schneck JP; Green JJ
ACS Appl Mater Interfaces; 2021 Feb; 13(7):7913-7923. PubMed ID: 33573372
[TBL] [Abstract][Full Text] [Related]
4. Surface-Engineering of Red Blood Cells as Artificial Antigen Presenting Cells Promising for Cancer Immunotherapy.
Sun X; Han X; Xu L; Gao M; Xu J; Yang R; Liu Z
Small; 2017 Oct; 13(40):. PubMed ID: 28861943
[TBL] [Abstract][Full Text] [Related]
5. PEGylated and CD47-conjugated nanoellipsoidal artificial antigen-presenting cells minimize phagocytosis and augment anti-tumor T-cell responses.
Song S; Jin X; Zhang L; Zhao C; Ding Y; Ang Q; Khaidav O; Shen C
Int J Nanomedicine; 2019; 14():2465-2483. PubMed ID: 31040669
[TBL] [Abstract][Full Text] [Related]
6. Artificial antigen-presenting cells expressing HLA class II molecules as an effective tool for amplifying human specific memory CD4(+) T cells.
Garnier A; Hamieh M; Drouet A; Leprince J; Vivien D; Frébourg T; Le Mauff B; Latouche JB; Toutirais O
Immunol Cell Biol; 2016 Aug; 94(7):662-72. PubMed ID: 26924643
[TBL] [Abstract][Full Text] [Related]
7. Paracrine release of IL-2 and anti-CTLA-4 enhances the ability of artificial polymer antigen-presenting cells to expand antigen-specific T cells and inhibit tumor growth in a mouse model.
Zhang L; Wang L; Shahzad KA; Xu T; Wan X; Pei W; Shen C
Cancer Immunol Immunother; 2017 Sep; 66(9):1229-1241. PubMed ID: 28501941
[TBL] [Abstract][Full Text] [Related]
8. Nanoscale artificial antigen presenting cells for T cell immunotherapy.
Perica K; De León Medero A; Durai M; Chiu YL; Bieler JG; Sibener L; Niemöller M; Assenmacher M; Richter A; Edidin M; Oelke M; Schneck J
Nanomedicine; 2014 Jan; 10(1):119-29. PubMed ID: 23891987
[TBL] [Abstract][Full Text] [Related]
9. Engineering Nanoscale Artificial Antigen-Presenting Cells by Metabolic Dendritic Cell Labeling to Potentiate Cancer Immunotherapy.
Xiao P; Wang J; Zhao Z; Liu X; Sun X; Wang D; Li Y
Nano Lett; 2021 Mar; 21(5):2094-2103. PubMed ID: 33622034
[TBL] [Abstract][Full Text] [Related]
10. Shape matters: Biodegradable anisotropic nanoparticle artificial antigen presenting cells for cancer immunotherapy.
Ben-Akiva E; Hickey JW; Meyer RA; Isser A; Shannon SR; Livingston NK; Rhodes KR; Kosmides AK; Warren TR; Tzeng SY; Schneck JP; Green JJ
Acta Biomater; 2023 Apr; 160():187-197. PubMed ID: 36812956
[TBL] [Abstract][Full Text] [Related]
11. Biomimetic Magnetosomes as Versatile Artificial Antigen-Presenting Cells to Potentiate T-Cell-Based Anticancer Therapy.
Zhang Q; Wei W; Wang P; Zuo L; Li F; Xu J; Xi X; Gao X; Ma G; Xie HY
ACS Nano; 2017 Nov; 11(11):10724-10732. PubMed ID: 28921946
[TBL] [Abstract][Full Text] [Related]
12. Towards efficient cancer immunotherapy: advances in developing artificial antigen-presenting cells.
Eggermont LJ; Paulis LE; Tel J; Figdor CG
Trends Biotechnol; 2014 Sep; 32(9):456-65. PubMed ID: 24998519
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy for Tumor Metastasis by Artificial Antigen-Presenting Cells via Targeted Microenvironment Regulation and T-Cell Activation.
Lu Y; Li L; Du J; Chen J; Xu X; Yang X; Ding C; Mao C
ACS Appl Mater Interfaces; 2021 Dec; 13(47):55890-55901. PubMed ID: 34787393
[TBL] [Abstract][Full Text] [Related]
14. A novel system of artificial antigen-presenting cells efficiently stimulates Flu peptide-specific cytotoxic T cells in vitro.
Han H; Peng JR; Chen PC; Gong L; Qiao SS; Wang WZ; Cui ZQ; Yu X; Wei YH; Leng XS
Biochem Biophys Res Commun; 2011 Aug; 411(3):530-5. PubMed ID: 21756876
[TBL] [Abstract][Full Text] [Related]
15. Nanoengineering approaches to the design of artificial antigen-presenting cells.
Sunshine JC; Green JJ
Nanomedicine (Lond); 2013 Jul; 8(7):1173-89. PubMed ID: 23837856
[TBL] [Abstract][Full Text] [Related]
16. Linking form to function: Biophysical aspects of artificial antigen presenting cell design.
Perica K; Kosmides AK; Schneck JP
Biochim Biophys Acta; 2015 Apr; 1853(4):781-90. PubMed ID: 25200637
[TBL] [Abstract][Full Text] [Related]
17. Development of third generation anti-EGFRvIII chimeric T cells and EGFRvIII-expressing artificial antigen presenting cells for adoptive cell therapy for glioma.
Sahin A; Sanchez C; Bullain S; Waterman P; Weissleder R; Carter BS
PLoS One; 2018; 13(7):e0199414. PubMed ID: 29975720
[TBL] [Abstract][Full Text] [Related]
18. Efficient amplification of melanoma-specific CD8+ T cells using artificial antigen presenting complex.
Chang J
Exp Mol Med; 2006 Dec; 38(6):591-8. PubMed ID: 17202834
[TBL] [Abstract][Full Text] [Related]
19. 4-1BB is superior to CD28 costimulation for generating CD8+ cytotoxic lymphocytes for adoptive immunotherapy.
Zhang H; Snyder KM; Suhoski MM; Maus MV; Kapoor V; June CH; Mackall CL
J Immunol; 2007 Oct; 179(7):4910-8. PubMed ID: 17878391
[TBL] [Abstract][Full Text] [Related]
20. Particle-Based Artificial Antigen-Presenting Cell Systems for T Cell Activation in Adoptive T Cell Therapy.
Hou F; Guo Z; Ho MT; Hui Y; Zhao CX
ACS Nano; 2024 Mar; 18(12):8571-8599. PubMed ID: 38483840
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
